| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/27/2001 | CA2188983C Pure 3r-3'r stereoisomer of zeaxanthin for treating macular degeneration in humans |
| 02/27/2001 | CA2188907C Combination compound for contraception based on natural estrogen |
| 02/27/2001 | CA2185165C Process for the synthesis of cationic surfactants derived from the condensation of fatty acids with esterified basic-character amino acids and their application as antimicrobial agents |
| 02/27/2001 | CA2124206C Indole derivatives |
| 02/27/2001 | CA2111204C Piperidine derivatives having anxiolytic effect |
| 02/27/2001 | CA2110582C Modified sialyl lewis a compounds |
| 02/27/2001 | CA2107485C Ellipticin derivatives, their preparation process and pharmaceutical compositions containing them |
| 02/27/2001 | CA2102454C Erythromycin derivatives, process for the preparation thereof, and use thereof as medicaments |
| 02/27/2001 | CA2101316C Gnrh analogs |
| 02/27/2001 | CA2081205C Steroids which inhibit angiogenesis |
| 02/27/2001 | CA2012267C Interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
| 02/27/2001 | CA1341187C Composition to induce and stimulate the growth of hair and/or slow down their shedding, based on a nonionic surfactant and a pyrimidine derivative |
| 02/26/2001 | CA2281010A1 Diagnostic method |
| 02/22/2001 | WO2001013117A2 Proteins, genes and their use for diagnosis and treatment of breast cancer |
| 02/22/2001 | WO2001012838A2 Compounds which modulate the activity of an lpa receptor |
| 02/22/2001 | WO2001012832A1 Process for producing lycopen |
| 02/22/2001 | WO2001012818A1 Neutral cerebral-sphingomyelinase |
| 02/22/2001 | WO2001012815A1 Coxsackie virus-derived vector system for gene transfer |
| 02/22/2001 | WO2001012811A1 C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| 02/22/2001 | WO2001012804A2 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
| 02/22/2001 | WO2001012787A2 Chimeric dna/rna ribozymes containing propanediol |
| 02/22/2001 | WO2001012781A1 13 human colon and colon cancer associated proteins |
| 02/22/2001 | WO2001012775A2 25 human secreted proteins |
| 02/22/2001 | WO2001012718A1 Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof |
| 02/22/2001 | WO2001012672A2 Cytokine receptor common gamma chain like |
| 02/22/2001 | WO2001012663A2 Hematopoietic regulatory factors and methods of use thereof |
| 02/22/2001 | WO2001012633A1 Water soluble sdz-rad esters |
| 02/22/2001 | WO2001012632A2 Phenanthroline-7-one derivatives and their therapeutic uses |
| 02/22/2001 | WO2001012631A2 Ascididemin derivatives and their therapeutic applications |
| 02/22/2001 | WO2001012629A1 Azaindoles having serotonin receptor affinity |
| 02/22/2001 | WO2001012628A1 Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation |
| 02/22/2001 | WO2001012627A1 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 02/22/2001 | WO2001012622A1 Piperidine and pyrrolidine derivatives displaying neuronal activity |
| 02/22/2001 | WO2001012621A1 INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
| 02/22/2001 | WO2001012618A1 Dihydroaminobenzo[b]- and [c]furans as retinoid-like agents |
| 02/22/2001 | WO2001012612A1 Benzoic acid derivatives for the treatment of diabetes mellitus |
| 02/22/2001 | WO2001012611A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/22/2001 | WO2001012607A2 Pharmaceutical compositions comprising 4-quinolones for treating cancers |
| 02/22/2001 | WO2001012606A2 Tetrahydroquinoline derivatives having retinoid-like biological activity |
| 02/22/2001 | WO2001012605A1 6,7-disubstituted-5,8-quinolinedione derivatives as an antifungal agent |
| 02/22/2001 | WO2001012603A1 Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application |
| 02/22/2001 | WO2001012602A1 Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands |
| 02/22/2001 | WO2001012601A1 Novel anilide derivatives or salts thereof and drugs containing the same |
| 02/22/2001 | WO2001012592A2 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/22/2001 | WO2001012591A1 Novel naphthylsulfonic acids and related compounds as glucose uptake agonists |
| 02/22/2001 | WO2001012590A1 Oxyme amides and hydrazone amides having fungicidal activity |
| 02/22/2001 | WO2001012584A2 Pharmaceutical compounds |
| 02/22/2001 | WO2001012579A2 New stilbenes with vascular damaging activity |
| 02/22/2001 | WO2001012265A1 Use of cyamemazine for cold turkey benzodiazepine treatment |
| 02/22/2001 | WO2001012264A2 Topical azathioprine for the treatment of oral autoimmune diseases |
| 02/22/2001 | WO2001012247A1 Tissue augmentation material and method |
| 02/22/2001 | WO2001012231A1 Method for delivery of therapeutic agents using a solution of dextrin |
| 02/22/2001 | WO2001012229A1 Pharmaceutical compositions for oral and topical administration |
| 02/22/2001 | WO2001012228A2 Compositions for treating viral infections, and methods therefor |
| 02/22/2001 | WO2001012227A1 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer |
| 02/22/2001 | WO2001012226A1 Angiogenesis inhibitors comprising as the active ingredient compound having chymase inhibitory effect |
| 02/22/2001 | WO2001012225A1 Water channel opener compositions and medicinal compositions for ophthalmic use |
| 02/22/2001 | WO2001012222A1 Immunological tolerance-induction agent |
| 02/22/2001 | WO2001012221A1 Therapeutic and prophylactic compositions including catalytic biomimetic solids and methods to prepare and use them |
| 02/22/2001 | WO2001012214A2 MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) |
| 02/22/2001 | WO2001012208A1 Use of ginkgo extract |
| 02/22/2001 | WO2001012206A2 Soy-glycine extracts and aromatase inhibitors for positively influencing collagen |
| 02/22/2001 | WO2001012204A2 Xanthine oxidase inhibitor containing compositions for the treatment of acetaminophen intoxication |
| 02/22/2001 | WO2001012203A1 Method of preventing adhesions with absorbable polyoxaesters |
| 02/22/2001 | WO2001012202A2 Use of chemical chelators as reversal agents for drug-induced neuromuscular block |
| 02/22/2001 | WO2001012201A1 Blood plasma replacement solution |
| 02/22/2001 | WO2001012200A1 An oral composition comprising coenzyme a for treating hyperlipemia, the preparation method and the use thereof |
| 02/22/2001 | WO2001012199A2 Methoxyamine potentiation of temozolomide anti-cancer activity |
| 02/22/2001 | WO2001012198A1 Remedies for myocardial infarction |
| 02/22/2001 | WO2001012197A1 Pyridomorphinans, thienomoprhinans and use thereof |
| 02/22/2001 | WO2001012196A1 Pyridomorphinans and use thereof |
| 02/22/2001 | WO2001012195A2 Use of morphine derivatives as medicaments for the treatment of neuropathic problems |
| 02/22/2001 | WO2001012194A1 Combinations with antithrombotic activity consisting of clopidogrel hydrogenosulphate and a gpiib/iiia receptor antagonist |
| 02/22/2001 | WO2001012193A1 Pharmaceutical agent comprising a benzamide derivative as active ingredient |
| 02/22/2001 | WO2001012192A2 Pharmaceutical compositions comprising a-(2-aminoethyl)-benzothiazolone and disodium cromoglycate or nedocromil |
| 02/22/2001 | WO2001012191A2 Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and a glucocorticoid |
| 02/22/2001 | WO2001012190A1 Partial agonists at the glycine modulatory site of the nmda receptor for treating cognitive dysfunction |
| 02/22/2001 | WO2001012189A1 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 02/22/2001 | WO2001012188A1 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 02/22/2001 | WO2001012187A2 Benzoic acid derivatives and their use as ppar receptor agonists |
| 02/22/2001 | WO2001012186A1 Cell adhesion inhibitors |
| 02/22/2001 | WO2001012185A1 Methods and compositions for bisubstrate inhibitors of acetyltransferases |
| 02/22/2001 | WO2001012184A1 Neurotherapeutic composition and method |
| 02/22/2001 | WO2001012183A1 Heterocycle amides as cell adhesion inhibitors |
| 02/22/2001 | WO2001012182A1 Use of proteinase inhibitor in order to inhibit the cleavage of growth factor precursor |
| 02/22/2001 | WO2001012181A1 Improved topical medicaments and methods for photodynamic treatment of disease |
| 02/22/2001 | WO2001012180A2 Peroxovanadium compounds as protein tyrosine phosphatase (ptp) inhibitors: their inhibitory effects on angiogenesis, restenosis and the production of endothelins, and their stimulating effects on the immune responce |
| 02/22/2001 | WO2001012179A1 Ophthalmic fluid |
| 02/22/2001 | WO2001012178A1 Method for isolating chlorogenic acid and 1,4-di-o-caffeoyl-d-(+)-quinic acid |
| 02/22/2001 | WO2001012177A1 Formation of nanometer-scale structures |
| 02/22/2001 | WO2001012176A2 Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity |
| 02/22/2001 | WO2001012175A1 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 02/22/2001 | WO2001012174A1 Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof |
| 02/22/2001 | WO2001012173A1 Low concentration pest treatment composition and method |
| 02/22/2001 | WO2001012171A2 Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases |
| 02/22/2001 | WO2001012170A2 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| 02/22/2001 | WO2001012169A2 Method of cancer treatment |
| 02/22/2001 | WO2001012168A2 Antiviral pharmaceutical compositions containing iron chelators |
| 02/22/2001 | WO2001012167A2 Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and an anticholinergic muscarinic antagonist |
| 02/22/2001 | WO2001012164A1 Oral form of administration containing probiotic micro-organisms |